ResearcherUniversity of Alabama at BirminghamActive in the last 2 years

Farrukh Afaq

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8612-0879; OpenAlex author ID A5090951584. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 11

Papers, trials and grants by year

2023: 1 paper · 2024: 1 paper

Papers 2

Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.neo.2023.100951 ↗
An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. Co-author DOI 10.1016/j.csbj.2023.11.029 ↗

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Upender Manne · 2 shared papers, 2023–2024 · strength 0.38
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
- Paper An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. DOI 10.1016/j.csbj.2023.11.029 ↗
Subhash C. Chauhan · 2 shared papers, 2023–2024 · strength 0.38
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
- Paper An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. DOI 10.1016/j.csbj.2023.11.029 ↗
Sooryanarayana Varambally · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Moh'd M. Khushman · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Sumit Agarwal · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Priyabrata Mukherjee · 1 shared paper, 2024 · strength 0.20
- Paper Targeting of oncogenic AAA-ATPase TRIP13 reduces progression of pancreatic ductal adenocarcinoma. DOI 10.1016/j.neo.2023.100951 ↗
Swati Dhasmana · 1 shared paper, 2023 · strength 0.18
- Paper An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. DOI 10.1016/j.csbj.2023.11.029 ↗
Murali Mohan Yallapu · 1 shared paper, 2023 · strength 0.18
- Paper An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. DOI 10.1016/j.csbj.2023.11.029 ↗
Shafiul Haque · 1 shared paper, 2023 · strength 0.18
- Paper An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. DOI 10.1016/j.csbj.2023.11.029 ↗
Anupam Dhasmana · 1 shared paper, 2023 · strength 0.18
- Paper An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. DOI 10.1016/j.csbj.2023.11.029 ↗
Sheema Khan · 1 shared paper, 2023 · strength 0.18
- Paper An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer. DOI 10.1016/j.csbj.2023.11.029 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.